Assessing the risk and prognosis of thrombotic complications in cancer patients

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 9, 2013, Pages 1286-1295

  Kyriazi, Vasiliki ^a   Theodoulou, Elisavet ^a  

^a LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; TUMOR MARKER;

BLEEDING; HUMAN; METABOLISM; NEOPLASM; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR RECURRENCE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VENOUS THROMBOEMBOLISM;

EID: 84885161371     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0490-RA     Document Type: Review

References (92)

1. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;32(1): 104-110. (Pubitemid 40262144)
2. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490-493.
3. Khorana AA. Cancer and coagulation. Am J Hematol. 2012;87(1):82-87.
4. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3): 484-490. (Pubitemid 46630468)
5. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembo-lism in the year before the diagnosis of cancer in 528, 693 adults. Arch Intern Med. 2005;165(15):1782-1787. (Pubitemid 41138968)
6. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrom-botic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722. (Pubitemid 40216041)
7. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy vs those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. (Pubitemid 29439263)
8. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(suppl 1):S2-S9.
9. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006; 119(1):60-68. (Pubitemid 43117468)
10. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93(2):298-305. (Pubitemid 40253735)
11. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous throembolism: a national, population-based cohort study. Br J Cancer. 2004;91(1):92-95. (Pubitemid 39013050)
12. El Sakka K, Gambhir RPS, Halawa M, Chong P, Rashid H. Association of malignant disease with critical leg ischaemia. Br J Surg. 2005;92(12):1498-1501. (Pubitemid 41785288)
13. Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004;2(6):876-881. (Pubitemid 40185732)
14. Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2(6):884-889. (Pubitemid 40185734)
15. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149(5):323-333.
16. Khorana AA, Conolly GC. Assessing risk of venous thromboembolism in the patients with cancer. J Clin Oncol. 2009;27(29):4839-4847.
17. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95. (Pubitemid 43054059)
18. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464.
19. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. (Pubitemid 350100757)
20. Simon T, De Jonage-Canonico B, Oger E, et al. Indicators of lifetime estrogen endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost. 2006;4(1):71-76.
21. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103(5):994-999. (Pubitemid 40270076)
22. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829. (Pubitemid 41798294)
23. Wun T, White R. Epidemiology of cancer-related venous thromboembo-lism. Best Pract Res Clin Haematol. 2009;22(1):9-23.
24. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. Vasc Med. 2011;16(2):119-130.
25. Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312-319.
26. Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26(4):563-571.
27. Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry. 2006;77(12):1336-1339. (Pubitemid 44851991)
28. Kennedy M, Andreescu AC, Greenblatt MS, et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005;128(3):386-388. (Pubitemid 40216162)
29. Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost. 2008;6(1):70-75.
30. Arslan S, Manduz S, Epöztürk K, Kaharan O, Akkurt I. Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases. Mol Biol Rep. 2011;38(4):2395-2400.
31. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2617V4F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-846. (Pubitemid 47267419)
32. De Stefano V, Za T, Rossi E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol. 2010;89(2):141-146.
33. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6(4):601-608. (Pubitemid 351404927)
34. Fotopoulou C, duBois A, Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26(16):2683-2689.
35. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25(1):70-76. (Pubitemid 350003053)
36. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006; 24(7):1112-1118. (Pubitemid 46638808)
37. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582-3586.
38. Kristinsson SY, Pfeiffer R, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991-4998.
39. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105(3):784-790. (Pubitemid 46734211)
40. De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3(9):1985-1992. (Pubitemid 43086055)
41. Feng DL, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420-2426. (Pubitemid 350145076)
42. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313-320. (Pubitemid 46878103)
43. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22(11):2020-2028.
44. Polycythemia vera: the natural history of 1213 patients followed for 20 years: Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656-664.
45. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17(2):297-303. (Pubitemid 43160121)
46. Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:437-444.
47. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431-436. (Pubitemid 46630462)
48. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
49. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-2285.
50. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-1239. (Pubitemid 47299901)
51. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280-2285.
52. McDonald CC, Alexander FE, Whyte B, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in woman receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group. BMJ. 1995;311(7011): 977-980.
53. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9(2):286-294.
54. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
55. Leaf AN, Propert K, Corcoran C, et al. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3282): an Eastern Cooperative Oncology Group study. Med Oncol. 2003;20(2):137-146.
56. Leuprolide versus diethylstillbestrol for metastatic prostate cancer: The Leuprolide Study Group. N Eng J Med 1984;311(20):1281-1286.
57. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996;14(8):2250-2257. (Pubitemid 26264875)
58. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol. 1986;136(3):624-631. (Pubitemid 16012495)
59. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708-714. (Pubitemid 43821788)
60. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(20):2079-2080.
61. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377-2381.
62. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455. (Pubitemid 37138770)
63. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394. (Pubitemid 351173321)
64. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963-968. (Pubitemid 38581515)
65. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003; 21(19): 3665-3675. (Pubitemid 46594061)
66. Lin J, Proctor MC, Varma M, Greenfield LJ, Upchurch GR, Henke PK. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg. 2003;37(5):976-983. (Pubitemid 36538919)
67. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15): 1653-1661. (Pubitemid 39037944)
68. Jurado J, Thompson PD. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer. 2005;44(7):620-624. (Pubitemid 40629211)
69. Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72(4):563-568.
70. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237-249.
71. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(1):4902-4907.
72. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13(10):2870-2875. (Pubitemid 46849560)
73. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer. J Thromb Haemost. 2012;10(7):1363-1370.
74. Ay C, Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res. 2010;125(suppl 2):S12-S15.
75. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-4129.
76. Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97(8):1158-1164.
77. Dogan M, Demirkazik A, Konuk N, et al. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study. Int J Biol Markers. 2006;21(4):206-210. (Pubitemid 46165210)
78. Vormittag R, Simanek R, Ay C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009;29(12):2176-2181.
79. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703- 2708.
80. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29(15):2099-2103.
81. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284-1297.
82. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-6840.
83. Zahra S, Anderson JA, Stirling D, Ludlam CA. Microparticles, malignancy and thrombosis. Br J Haematol. 2011;152(6):688-700.
84. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382.
85. Kuderer NM, Francis CW, Culakova E, et al. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy. J Clin Oncol. 2008;26(15S):Abstract 9521. http://meeting.ascopubs.org/cgi/content/abstract/26/ 15suppl/9521?sid0d918226-7daa-46c4-87ce-110bfecbe4e7. Date accessed: November 12, 2012.
86. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. (Pubitemid 46680709)
87. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboem-bolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. (Pubitemid 35303914)
88. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000; 18(17):3078-3083.
89. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism: findings from the RIETE Registry. Thromb Haemost. 2008;100(3):435-439.
90. Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost. 2008;6(12):2075-2581.
91. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10): 1037-1052.
92. Pengo V, Lensing AW, Prins MH, et al; and Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350(22):2257-2264.